A promising leap in treating large granular lymphocytic leukemia: reflections on a Multicenter Phase II Study of thalidomide-based therapy.
Publication
, Journal Article
Kong, X; Young, KH
Published in: Blood Sci
September 2025
Duke Scholars
Published In
Blood Sci
DOI
EISSN
2543-6368
Publication Date
September 2025
Volume
7
Issue
3
Start / End Page
e00239
Location
United States
Citation
APA
Chicago
ICMJE
MLA
NLM
Kong, X., & Young, K. H. (2025). A promising leap in treating large granular lymphocytic leukemia: reflections on a Multicenter Phase II Study of thalidomide-based therapy. Blood Sci, 7(3), e00239. https://doi.org/10.1097/BS9.0000000000000239
Kong, Xue, and Ken H. Young. “A promising leap in treating large granular lymphocytic leukemia: reflections on a Multicenter Phase II Study of thalidomide-based therapy.” Blood Sci 7, no. 3 (September 2025): e00239. https://doi.org/10.1097/BS9.0000000000000239.
Kong X, Young KH. A promising leap in treating large granular lymphocytic leukemia: reflections on a Multicenter Phase II Study of thalidomide-based therapy. Blood Sci. 2025 Sep;7(3):e00239.
Kong, Xue, and Ken H. Young. “A promising leap in treating large granular lymphocytic leukemia: reflections on a Multicenter Phase II Study of thalidomide-based therapy.” Blood Sci, vol. 7, no. 3, Sept. 2025, p. e00239. Pubmed, doi:10.1097/BS9.0000000000000239.
Kong X, Young KH. A promising leap in treating large granular lymphocytic leukemia: reflections on a Multicenter Phase II Study of thalidomide-based therapy. Blood Sci. 2025 Sep;7(3):e00239.
Published In
Blood Sci
DOI
EISSN
2543-6368
Publication Date
September 2025
Volume
7
Issue
3
Start / End Page
e00239
Location
United States